-
Mural Oncology plc NasdaqGM:MURA Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Location: 10 Earlsfort Terrace, Dublin, D02 T380, Ireland | Website: https://www.muraloncology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-55.15M
Cash
107.7M
Avg Qtr Burn
-32.0M
Short % of Float
8.15%
Insider Ownership
13.17%
Institutional Own.
55.38%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nemvaleukin alfa +/- pembrolizumab Details Cancer, Melanoma | Phase 2 Data readout | |
Nemvaleukin alfa (ALKS 4230) (IL-2) Details Solid tumor/s, Cancer | Phase 1/2 Update | |
Nemvaleukin alfa + pembrolizumab Details Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer | Failed Discontinued |